DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a formal response has been filed to a Citizen Petition submitted to the Food and Drug Administration on June 7, 2011 regarding the Company’s pending New Drug Application (NDA) for its lead radiopharmaceutical product, Lymphoseek®. The response was filed by Patton Boggs, Neoprobe Corporation’s counsel for regulatory matters, and addresses the core arguments of the petition filed with FDA by a third party which contains inaccurate and misleading statements about the science underlying Lymphoseek and FDA-regulated clinical trials.
